A B S T R A C T Hypertyraminemia is common in hepatic cirrhosis and correlates in severity with encephalopathy. The mechanism of cirrhotic hypertyraminemia has not been established. The alternative possibilities are increased production from tyrosine and impaired degradation by monoamine oxidase. This investigation determined the pharmacokinetics of tyramine after an intravenous bolus injection of [3H]-tyramine uCi, 12 Ci/mmol sp act) in 13 cirrhotics and 9 controls. In normals, [3H]tyramine levels initially declined rapidly (a-phase) followed by a slower decline (,8-phase) with an average t1/2 of20.8 min. Average normal metabolic clearance rate and production rate were 13.2 liters/min and 15.4 ,ug/min, respectively.
INTRODUCTION
Tyramine concentration is abnormally elevated in the plasma of cirrhotic patients (1) . Tyramine is the precursor of octopamine. Octopamine acts as a central "false neurotransmitter" and tyramine acts as an indirect sympathomimetic agent. Both have potent ef-fects on circulatory and neurologic functions, which are often disturbed in cirrhotics (1) (2) (3) (4) (5) . An understanding of the mechanism of the hypertyraminemia of cirrhotic patients is therefore desirable. The accumulation of tyramine in plasma could result from increased production, decreased degradation, or a combination of both effects.
Tyramine is produced by decarboxylation of tyrosine ( Fig. 1) . Plasma tyrosine is elevated in cirrhotics (6) (7) (8) , and tyrosine tolerance is impaired (9) , therefore more tyrosine is available for tyramine formation than in normals. Tyramine is also produced in the gastrointestinal tract by bacterial decarboxylation of tyrosine and may enter the systemic circulation via portasystemic shunts.
Tyramine is degraded by monoamine oxidase, of which the major proportion is located in the liver. Accordingly, tyramine degradation could be delayed in cirrhosis because ofhepatocellular disease, diminished hepatic blood flow, or both.
In this study, we have measured the production rate and metabolic clearance rate of plasma tyramine in normals and in cirrhotics with a pharmacokinetic technique. The kinetics of tyramine were correlated with the clinical status of the liver patients, the fasting plasma tyrosine, and the tyrosine tolerance. A hypothesis relating hypertyraminemia and hypertyrosinemia was developed from the results.
METHODS

Materials
[3H]Tyramine (11.6 Ci/mmol sp act) was obtained from New England Nuclear (Boston, Mass.). Radiochemical purity, evaluated by analytic thin-layer chromatography with three different solvent systems (10) , was >98%. Tyramine and octopamine were purchased from Sigma Chemical Co. (St. Louis, Mo.). p-Hydroxyphenylacetic acid was obtained from Aldrich Chemical Co., Inc. (Milwaukee, Wis.), and phydroxyphenethanol was synthesized according to a published procedure of Kiefer (11 
Subjects
The control group consisted of 11 healthy adult volunteers, 9 males and 2 females, with no history of hepatobiliary disease and with normal conventional liver tests. The experimental group consisted of 13 patients with cirrhosis, 9 males and 4 females, ages 19-63 yr (7 Laennec's, 2 primary biliary, 2 postnecrotic, and 2 chronic active hepatitis with cirrhosis).
Cirrhosis was documented by liver biopsy. All subjects gave informed consent. The investigation was approved by the Emory University Clinical Investigation Committee. The clinical data of group II was summarized in Tables I and II. Each cirrhotic patient received a full liver evaluation before commencement of the [3H]tyramine studies, as follows.
Serum levels of serum glutamic oxaloacetic transaminase, alkaline phosphatase, albumin, bilirubin, and prothrombin times were measured according to standard laboratory techniques. A modified child's classification was used to grade the severity of liver disease. Fasting venous plasma ammonia quantitation was measured colorimetrically by a modified method of Forman (13) . Quantitative tests of hepatic function included galactose elimination capacity (14) and antipyrine clearance and half-life (15, 16) .
Neurologic and electroencephalographic evaluations were done according to Parsons-Smith et al. (17) . The clinical history was considered positive for encephalopathy when mental confusion, disorientation, or asterixis had occurred unrelated to gastrointestinal bleeding, electrolyte imbalance, infection, or drugs. Psychometric testing was used to detect more subtle mental aberrations (18 The samples were centrifuged immediately as above, and Kodak Co., Rochester, N. Y.) was added and the mixture was then the plasma was removed and quickly frozen at -80°C shaken vigorously (vortex for 1 min). Upon centrifugation until analysis. Urine samples were collected into polyethylene (500g for 20 min), an aliquot of the supernate (pH 1.5) bottles containing 10 ml 6 N HC1 at 6-h intervals for 2 con-was removed and placed in a 50-ml glass-stoppered centrifuge secutive d to ensure complete excretion of the radioactivity. tube (Kontes Co., Vineland, N. J.). Upon addition of 2 g The samples were frozen at the end of the collection and NaCl, 0.3 g anhydrous Na2CO3, 4 ml of 0.5 M buffer (sodium stored at -80°C until analysis. borate, adjusted to pH 10.5 with 10 N NaOH), and 30 ml of ethyl acetate, the mixture was shaken (model S-500, Kraft
Analytical methods
Apparatus, Inc.,) for 30 min and then centrifuged for 10 min.
An aliquot (25 ml) of the organic phase was removed. To ENDOGENOUS TYRAMINE IN PLASMA the two-phase mixture, 10 ml of ethyl acetate was added after Extraction procedure. Tyramine in plasma (usually 1 ml) shaking and centrifuging as above, 10 ml of solvent was was extracted according to the following procedure. To an withdrawn. The combined fractions of ethyl acetate (35 ml) Radioimmunoassay procedure. The method used was a modification of that described by Faraj et al. (12) . In 12 x 75-mm plastic tubes (Lab-Tek culture tube, Lab-Tek Products, Div. Miles Laboratories Inc., Naperville, Ill.) were placed 0.3 ml of 0.5% bovine serum albumin wt/vol in 0.2 M sodium phosphate buffer solution (pH 7.4). We then added 0.1 ml of antibody solution (1:50), 0.1 ml of [3H]tyramine (0.16 ng, 7,500 cpm) in phosphate buffer, and either unlabeled tyramine (0.5-10 ng for standard curve) or 0. 1-ml aliquot of the sodium phosphate buffer (pH 7.4) containing the extracted tyramine. The tubes were capped and incubated at 4°C for 2 h. Antibody-bound [3H]tyramine was separated from tyramine by the addition of 0.5 ml aqueous polyethylene glycol 6,000 (30% wt/vol) as described by Cheung and Slaunwhite (20) . The tubes were vortex mixed vigorously and centrifuged (2, Fasting plasma samples were withdrawn from a peripheral vein at 0, 0.5, 1.5, 3, 3.5, 6, 7.5, and 9 h after ingestion. The samples were immediately cooled, centrifuged at 500 g for 10 min, and the plasma frozen at -80°C until deproteinized and analyzed for free tyrosine. The tyrosine tolerance score was calculated by obtaining the area under the plasma tyrosine concentration vs. time curve using the trapezoidal rule (22) .
RADIOASSAY OF [3H]TYRAMINE AND ITS
METABOLITES
Determination of total radioactivity in plasma and urine. Aliquots (0.3 ml) of urine and plasma were placed in liquid scintillation vials and counted as above. The total tritium content was expressed as cpm-' per milliliter of sample. Instrument counting efficiency for 3H was 45%.
Separation of radioactivity in plasma and urine into basic and acidic fractions. 'Abbreviations used in this paper: AUC, plasma concentration vs. time curves; MCR, metabolic clearance rate; PR, production rate. PR = MCR x Ci, where Ci is the endogenous tyramine concentration (ng/ml) in the plasma pool. Tyramine concentrationi was measured in every specimen and the results are showin in Fig. 2 . Half-life was determined by the least squares method from the log-linear terminal portion of the curve.
Statistical analysis
The results obtained in each series of experiments are expressed as the arithmetic mean and standard error (SEM). T-he samiiple means were compared by the Student's t test for paired data when appropriate. Values ofP < 0.05 were accepted as representing significant differences.
RESULTS
Plasmica levels of tyramine and tyrosine; correlations witl clinical data. Normal fasting tyrosine was ,uLnol/liter. All 13 cirrhotic patients had fasting tyrosiniemia (Table II) . The four patients who received an oral tyrosine tolerance test also showed marked impairmienit in the plasma clearance ofthis amino acid. Normal plasma tyramine was 1.2 ng/ml. Plasma tyramine was elevated in 9 of the 13 cirrhotics (Table IL) .
The degree of tyrosinemia and tyraminemia was (lirectly correlated with antipyrine half-life and galactose elimination capacity (r = 0.901, P < 0.002; Table  I ). In addition, plasma tyrosine levels were also sigriificanitly correlated with prothrombin time (r = 0.750, P < 0.003) and the child's score (r = 0.55, P < 0.05). Only 1 of the 13 patients had clinical encephalopathy. 10 eirrhotics had mild psychomotor impairment. Cardiac output and creatinine clearance were normal in 67% of the patients. Neither cardiac output nor creatiniine clearance correlated significantly with plasma tyrosii e or tyramine.
Plasma tyramine concentrations at determined initervals. In both the cirrhotic and the control sub- (Fig. 2) .
[3H]Tyramine metabolism. In normal subjects, the plasma disappearance curve for [3H]tyramine and total 3H indicated a multiexponential pattern becoming monoexponential at _8-10 min after dose administration. For [3Hjtyramine two components were resolvable from the curves of [3H]tyramine concentration (cpm/ml) and [3H]tyramine specific activity (cpm/ng) ( Fig. 3A and B) . The initial distribution phase (a) and the elimination phase (,8) (Fig. 3A and B) . Radiochromatographic analysis indicated that most 3H in plasma consisted of products obtained from the oxidative deamination of [3H]tyramine (4-hydroxyphenylacetic acid and 4-hydroxyphenethanol in the ratio of 70:30).
In patients with cirrhosis, the plasma disappearance curve for [3H]tyramine was similar to that of the control subjects with no apparent difference in the half-life (,p-phase, 17.2 min). The PR of tyramine (average 32 ,tg/min) in cirrhotics was significantly greater (P < 0.05) than that of normal subjects (average 15.4 ,ug/min). In contrast, there was no difference in the MCR of tyramine in cirrhotics (average 12.2 liter/min) as compared with control subjects (average 13.2 liters/min) (Table III) . The profile of [3H]tyramine metabolism in the cirrhotic patient was markedly different when compared with that of the control subjects. There was a fourfold increase in the ratio of 4-hydroxyphenylethanol to that of 4-hydroxyphenylacetic acid in cirrhotic patients as compared with control subjects (60:40 vs. 30:70 in controls).
After the single intravenous administration of [3H]-tyramine to normal subjects, radioactivity was present in the urine 6 h after dose administration: 48 h later 90-95% of the administered radioactivity had been recovered in the urine. Chromatographic analysis of the urine showed that [3H]4-hydroxyphenylacetic acid accounted for 80-85% of the radioactivity, whereas [3H]tyramine accounted for only 2-5% (Fig. 4) . This same pattern was found in the cirrhotics. Tables I and II. tyramine, and its f8-hydroxylated derivative octopamine, have also been found in cirrhotics (1) (2) (3) (4) (5) . The objective of this study is to determine whether tyramine accumulation in plasma is the result of accelerated production or decreased elimination. In The plasma tyramine production rate measurements made in this study do not imply sampling of the total body production oftyramine. Rather, the determinations represent production into that portion of the tyramine pool with which tyramine in plasma is miscible. The rate of tyramine input into the pool being sampled (peripheral plasma) does not detect tyramine input into other noncommunicating pools. An example of such a pool might be tyramine produced in the gut, absorbed into the portal vein, and eliminated by the liver on first pass. This tyramine does not reach the peripheral plasma and so is not measured. It must be noted that the plasma production rate method will not discriminate between endogenously produced tyramine and tyramine reaching the circulation because of decreased first pass clearance through the liver. Our results indicate, however, that once in peripheral plasma, tyramine is cleared in a quantitatively similar manner in normals and cirrhotics.
We found that the hypertyraminemia of cirrhosis results primarily from overproduction of the amine. PR in the cirrhotics was significantly greater than in the controls. The metabolic clearance rate, i.e., plasma cleared of tyramine per minute, elimination half-life, and volume of distribution remained normal. When plasma tyramine was elevated in cirrhotics, the amount of tyramine cleared per minute did not decrease but increased in parallel with the PR. Thus the data indicated that a rise in production was the primary event; as plasma tyramine increased, plasma volume cleared per unit time generally remained constant, and plasma tyramine concentration rose until the amount of tyramine cleared per unit time, i.e. (plasma clearance x plasma concentration), increased to equal the PR.
We found evidence suggesting that although the MCR was the same in cirrhotics and controls, the clearance mechanism may not be entirely normal in cirrhotics. The metabolic pathways oftyramine are shown in Fig. 1 Fasting tyrosine was elevated two to four times in all hypertyraminemic patients, and clearance of an oral load of tyrosine was retarded, suggesting impaired capacity of the hepatic oxidative pathway. This process normally metabolizes > 90% of dietary tyrosine. David et al. (24) have shown that endogenous production of tyramine from tyrosine via decarboxylation becomes a major pathway for the catabolism of tyrosine when the dietary intake of this amino acid increases to three times the minimal daily requirement. Further support for this hypothesis comes from our demonstration of impaired metabolism of both 4-hydroxyphenylpyruvic and homogentisic acids in hypertyraminemic cirrhotics, compatible with blocks at the levels of the two corresponding hepatic oxidases (25) . Finally, when dietary tyrosine is increased in cirrhotics, plasma tyrosine and plasma tyramine rise in parallel (1) .
It is possible that some of the overproduction of tyramine from tyrosine could result from the gastrointestinal bacterial decarboxylases rather than from the patient's tissue decarboxylases. Portasystemic shunting would permit the bacterial product to circumvent the first pass effect of hepatic monoamine oxidase and enter the peripheral plasma.
With regard to the possible clinical consequences of the accumulations of tyramine and octopamine, Fischer and Baldessarini (2) have suggested that these amines may cause lowering of peripheral resistance with resultant high cardiac output, reduction in renal function, and cerebral dysfunction in cirrhotic patients. In our series, almost all patients had normal cardiac output, creatinine clearance, and electroencephalograms, so our data do not shed light on this issue. However, if the present methods are applied in the future to hyperdynamic, azotemic, or encephalopathic cirrhotic patients, the role of hypertyraminemia in these complications can be examined.
